SCHEMBL6736294

SCHEMBL6736294

CS(=O)(=O)c1cc(F)c(-c2cnccc2-c2ccc(C(F)(F)F)cc2)cc1F

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SLC22A12 Q96S37 2/20 0.53
ALOX5AP P20292 2/20 0.47
FEN1 P39748 2/20 0.47
PTGS2 P35354 4/20 0.46
NR1H2 P55055 2/20 0.42
NR1H3 Q13133 2/20 0.42
PTGS1 P23219 1/20 0.42
APP P05067 1/20 0.41
KIF11 P52732 2/20 0.40
GPBAR1 Q8TDU6 2/20 0.39
RPS6KA3 P51812 2/20 0.39
POLB P06746 1/20 0.39
CYP11B1 P15538 1/20 0.39
CYP11B2 P19099 1/20 0.39
IDO1 P14902 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6732701 0.88 PTGS2 (0.50) SLC22A12PTGS2RPS6KA3
SCHEMBL6736544 0.87 NR1H2 (0.49) SLC22A12ALOX5APFEN1PTGS2NR1H2
SCHEMBL7111106 0.87 SLC22A12 (0.54) SLC22A12ALOX5APFEN1PTGS2NR1H2
SCHEMBL6734300 0.86 RPS6KA3 (0.53) SLC22A12PTGS2PTGS1RPS6KA3
SCHEMBL6732643 0.85 PTGS2 (0.48) SLC22A12ALOX5APFEN1PTGS2NR1H2
SCHEMBL6737143 0.85 PTGS2 (0.48) SLC22A12PTGS2PTGS1RPS6KA3
SCHEMBL6732156 0.85 PTGS2 (0.44) SLC22A12ALOX5APFEN1PTGS2NR1H2
SCHEMBL6739704 0.85 RPS6KA3 (0.50) SLC22A12ALOX5APFEN1PTGS2NR1H2
SCHEMBL6736152 0.84 NR1H2 (0.46) SLC22A12ALOX5APFEN1PTGS2NR1H2
SCHEMBL6739459 0.84 NR1H2 (0.46) SLC22A12ALOX5APFEN1PTGS2NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US claimed
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2004-07-15 US disclosed
US-6699884-B2 ANTIINFLAMMATORY CYCLOOXYGENASE INHIBITORS. PHARMACIA CORPORATION 2004-03-02 US disclosed
US-6673818-B2 TREATING CYCLOOXYGENASE-2 MEDIATED DISORDERS, SUCH AS ARTHRITIS, PAIN, FEVER AND CANCER PHARMACIA CORPORATION 2004-01-06 US disclosed
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-08-07 US disclosed
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-02-13 US disclosed
EP-1251126-A2 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation Pharmacia Corporation (US) 2002-10-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040138261-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 SLC22A12 4211/4885ALOX5AP 603/4885FEN1 1023/4885
US-20030149078-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 SLC22A12 4211/4885ALOX5AP 603/4885FEN1 1023/4885
US-20030032657-A1 Fluoro-substituted benzenesulfonyl compounds for the treatment of inflammation FPR1, FPR2, FPR3 SLC22A12 4211/4885ALOX5AP 603/4885FEN1 1023/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.